Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm

Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory sign...

Full description

Bibliographic Details
Main Authors:	Yoshimura, Koichi, Aoki, Hiroki
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432368/

id	pubmed-3432368
recordtype	oai_dc
spelling	pubmed-34323682012-09-06 Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm Yoshimura, Koichi Aoki, Hiroki Review Article Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA. Hindawi Publishing Corporation 2012 2012-08-21 /pmc/articles/PMC3432368/ /pubmed/22957259 http://dx.doi.org/10.1155/2012/648167 Text en Copyright © 2012 K. Yoshimura and H. Aoki. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Yoshimura, Koichi Aoki, Hiroki
spellingShingle	Yoshimura, Koichi Aoki, Hiroki Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
author_facet	Yoshimura, Koichi Aoki, Hiroki
author_sort	Yoshimura, Koichi
title	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
title_short	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
title_full	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
title_fullStr	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
title_full_unstemmed	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
title_sort	recent advances in pharmacotherapy development for abdominal aortic aneurysm
description	Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA.
publisher	Hindawi Publishing Corporation
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432368/
_version_	1611553751347232768

Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm

Similar Items